Scaling Care for Millions. Instantly.
Our mission is to relieve overburdened global healthcare systems, resolve specialist scarcities, and advance longevity through fully autonomous, affordable, and universally accessible AI-driven diagnostics—pioneering the field of oculomics by utilizing the human retina as a non-invasive window into systemic health.
From overloaded specialty care to accessible primary screening.
Fragmented care paths and specialist burnout.
Long appointment backlogs, fragmented hand-offs and growing populations of chronic patients are pushing retinal specialists past sustainable capacity. The patients who most need early detection are the ones least likely to ever reach a clinic in time.
A fast, painless, non-mydriatic screen any healthcare professional can run.
A near-instant screening procedure performed successfully by any trained healthcare professional — requiring no local ophthalmologist capacity during the test, and producing a clinical report at the point of care.
EU MDR Class IIb certified medical device
Aireen is a CE-marked medical device developed under a certified ISO 13485 quality management system. It is intended for the screening of diabetic retinopathy and the detection of signs of AMD present in fundus images, in line with its approved intended purpose.
Aireen does not replace a full ophthalmological examination. It is designed to detect only signs of disease present in the available fundus images. For the complete intended purpose, indications, contraindications and user requirements, refer to the Instructions for Use.
- CE marking as a Class IIb medical device under Regulation (EU) 2017/745 (MDR)
- Notified Body assessment (CE 2265)
- Used within its intended purpose as described in the Instructions for Use
Certified quality management system for design, development, configuration, sale, installation and service of software devices.
Certified information security management system covering the development, provision and support of Aireen's medical-device SaaS. Certificate No. I-0225C/25, valid 29.04.2025 – 29.04.2028, issued by 3EC International.
The team behind certified autonomous screening.
Clinical and scientific advisors.
1,000,000 screened patients within 3 years.
Our trajectory is to deliver autonomous retinal screening to one million treated patients across primary global medical markets — the Americas and EMEA